课题基金 / 基金详情

Role of BAZ2A in MLL-r leukemia and therapeutic response

Role of BAZ2A in MLL-r leukemia and therapeutic response
BAZ2A 在 MLL-r 白血病中的作用和治疗反应
批准号:
10356863
负责人:
Chun-Wei David Chen
金额:
$39.57万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2024-03-31

项目摘要

项目成果

Chun-Wei David Chen的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 MLL重排(MLL-r)白血病占人类急性白血病的5%-10%,与 预后不良。临床需求未得到满足,缺乏有效的靶向治疗 白血病强调了新疗法的必要性。最近的癌症表观遗传学研究发现 组蛋白H3赖氨酸79(H3K79)甲基转移酶DOT1L在MLL-r白血病发生中的中心作用。 已经注意到将DOT1L抑制剂作为单一药物治疗的重要临床反应,然而, 预计联合治疗将是必要的。 我们基于DOT1L抑制剂增敏筛查的MLL-r白血病的初步研究已经确认 抑制BAZ2A显著增加DOT1L抑制剂的抗白血病活性。目标是 这一应用的目的是确定介导SIRT1可用于 抑制MLL-r白血病的癌基因表达。我们的中心假设是BAZ2A,一种染色质 RDNA基因座重塑蛋白介导组蛋白去乙酰化和沉默SIRT1的重新分布 MLL-r/DOT1L驱动的癌基因。我们将剖析BAZ2A/SIRT1染色质靶向机制(目标1), 研究DOT1L和BAZ2A联合疗法的疗效(目标2),并验证一种新的饱和度 CRISPR蛋白质扫描技术用于DOT1L和BAZ2A功能元件的新发现 (目标3)。 本研究的创新之处在于:(1)引入了同时瞄准多个目标的新概念 表观遗传网络的组成部分,以有效地抑制癌症计划,以及(2)它建立了一种 全新的基因筛选方法,用于亚蛋白质水平的功能域发现。这件事的影响 研究将具有重要意义,因为(1)它立即提供了新的治疗机会 针对难治性的MLL-r白血病,以及(2)它将有助于识别新的功能元件 表观遗传调节器,用于未来的药物靶向。
英文摘要
PROJECT SUMMARY/ABSTRACT MLL-rearranged (MLL-r) leukemias account for 5-10% of human acute leukemia and is associated with poor prognosis. The unmet clinical needs and the lack of an effective targeted therapy to the MLL-r leukemias emphasize the need for novel regimens. Recent cancer epigenetics studies discovered a central role for the histone H3 lysine 79 (H3K79) methyltransferase DOT1L in MLL-r leukemogenesis. Important clinical responses have been noted with DOT1L inhibitor treatment as a single agent, however, it is expected that combination treatments will be necessary. Our preliminary studies based on a DOT1L-inhibitor sensitization screen in MLL-r leukemia have identified suppression of BAZ2A significantly increases the anti-leukemic activity of the DOT1L inhibitor. The objective of this application is to determine the critical epigenetic mechanisms that mediate the availability of SIRT1 to suppress oncogene expression in MLL-r leukemia. Our central hypothesis is that BAZ2A, a chromatin remodeling protein of rDNA loci, mediates redistribution of SIRT1 for histone deacetylation and silencing of MLL-r/DOT1L-driven oncogene. We will dissect the BAZ2A/SIRT1 chromatin targeting mechanisms (Aim 1), investigate the efficacy of DOT1L and BAZ2A combination therapies (Aim 2), and validate a novel saturation CRISPR protein scan technology for de novo discovery of the functional elements in DOT1L and BAZ2A (Aim 3). This study is innovative because (1) it introduces a novel concept of simultaneously targeting multiple components of an epigenetic network to efficiently suppress the cancer programs, and (2) it establishes a brand new genetic screen approach for a sub-protein level functional domain discovery. The impact of this research will be of significance because (1) it immediately provides novel therapeutic opportunities against the difficult-to-treat MLL-r leukemias, and (2) it will help identify novel functional elements in epigenetic regulators for future pharmaceutical targeting.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism and therapeutic opportunities of targeting the Tudor domain
Integrative Analyses of Saturation CRISPR Protein Scan
Role of BAZ2A in MLL-r leukemia and therapeutic response
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
海外基金